Allogeneic Cell Therapy Market by Type of Cell Therapy, Source of Cell, Target Indication, Therapeutic Area, and Key Geographical Regions

As per Roots Analysis, the global allogenic cell therapy market is estimated to grow from USD 0.98 billion in the current year to USD 2.74 billion by 2035, at a CAGR of 5.9% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Cell Therapy

Stem Cell
Virus-Specific T-Cell
Regulatory T-Cell

Source of Cell

Bone Marrow / Matrix
Adipose Tissue
Peripheral Blood
Umbilical Cord
Placenta
Others

Target Indication

Infectious Diseases
Chronic Heart Failure
Crohn's Disease
Ischemic Stroke
Hematological Cancer
Bone Diseases
Critical Limb Ischemia
Graft versus Host Disease
Duchenne Muscular Dystrophy
Epidermolysis Bullosa
Diabetic Foot Ulcer
Others

Therapeutic Area

Post-Transplant Infections
Cardiovascular Disorders
Autoimmune / Inflammatory Disorders
Cerebrovascular Disorders
Oncological Disorders
Musculoskeletal Disorders
Neurological Disorders
Genetic Disorders
Others

Key Geographical Regions

North America
Europe
Asia-Pacific and Rest of the World

ALLOGENEIC CELL THERAPY MARKET: GROWTH AND TRENDS

Cell therapy refers to the administration of engineered cells into a patient's body in order to replace the damaged tissues or to modulate the cell functioning through direct interaction or expression of factors. Depending on its source, cell therapies can either be autologous (derived from the patient's own body) or allogeneic (derived from a healthy donor).

Allogenic cell therapy, often referred to as "off-the-shelf" cell therapy, is a form of regenerative medicine that involves the use of cells from a donor, rather than the patient themselves. These cells can be derived from various sources, such as bone marrow, umbilical cord blood, or induced pluripotent stem cells (iPSCs). Unlike autologous cell therapy, where a patient's own cells are used, allogenic cell therapy provides several distinct advantages. One of the key applications of allogeneic cell therapy is in the treatment of various diseases, such as cancer, autoimmune disorders, and degenerative conditions. In fact, according to the Alliance for Regenerative Medicine, the number of clinical trials being conducted for allogeneic cell-based cancer therapies increased by 30% over the past five years. Further, it is worth mentioning that these cells can be genetically modified to enhance their therapeutic properties, making them more effective at targeting and destroying disease cells or promoting tissue repair.

ALLOGENEIC CELL THERAPY MARKET: KEY INSIGHTS

The report delves into the current state of the allogeneic cell therapy market and identifies potential growth opportunities within the industry. Some key findings from the report include:

Over 480 allogeneic cell therapies are either approved or being investigated in research studies by more than 190 players; the market landscape features the presence of both established players and new entrants.
The majority of the clinical-stage allogeneic cell therapies are being evaluated in phase II trials; these therapies are being derived from different sources of cells and target multiple disease indications.

More than 365 clinical trials (with over 18,000 enrolled patients) are currently underway to investigate allogeneic cell therapies across different geographies.
The rising interest of stakeholders in this domain is reflected in the wide array of partnerships established by allogeneic cell therapy developers with various international and indigenous partners.
Having realized the opportunity in this segment, several investors have invested around USD 8.8 billion (across 120 funding instances), in the past five years; the maximum amount was invested through venture capital rounds.
Various KOLs affiliated to academic / medical / commercial organizations are evaluating the efficiency of allogeneic cell therapies in different disease indications.
Driven by the rising incidence of chronic diseases and growing demand for novel allogeneic cell therapies, this market is anticipated to grow at a CAGR of 5.9%, till 2035.

The projected future opportunity for allogeneic cell therapies is likely to be well distributed across different types of target indications, therapeutic areas and key geographical regions.

ALLOGENEIC CELL THERAPY MARKET: KEY SEGMENTS

Regulatory T-Cell Therapies is the Fastest Growing Segment of the Allogeneic Cell Therapy Market

Based on the type of cell therapy, the global market for allogeneic cell therapy is segmented into stem cell, virus-specific T cell and regulatory T-cell therapies. Currently, the majority share of the allogeneic cell therapy market is captured by stem cell therapies. It is worth mentioning that the regulatory T-cell therapies segment is likely to grow at a higher CAGR (~ 23%) in the coming years.

By Source of Cell, Bone Marrow / Matrix Segment Dominates the Global Allogeneic Cell Therapy Market

Based on the source of cells, the market is segmented into bone marrow / matrix, adipose tissue, peripheral blood, umbilical cord, placenta and others. Currently, the market is dominated by bone marrow / matrix-derived allogenic cell therapies, capturing the highest proportion of the allogeneic cell therapy market. It is worth highlighting that the global allogeneic cell therapy market for the adipose tissue-derived therapies segment is likely to grow at a relatively higher CAGR.

Infectious Diseases Segment is Likely to Hold the Largest Share of the Allogeneic Cell Therapy Market During the Forecast Period

Based on the target indication, the market is segmented into infectious diseases, chronic heart failure, Crohn's disease, ischemic stroke, hematological cancer, bone disease, critical limb ischemia, graft versus host disease, Duchenne muscular dystrophy, epidermolysis bullosa, diabetic foot ulcer and others. At present, the infectious diseases segment holds the majority share of the global allogeneic cell therapy market. Notably, epidermolysis bullosa target indication segment is likely to grow at a relatively higher CAGR.

By Therapeutic Area, Allogeneic Cell Therapies for Post-Transplant Infections are Likely to Dominate the Market During the Forecast Period

Based on the therapeutic area, the global market for allogeneic cell therapy is distributed across post-transplant infections, cardiovascular disorders, autoimmune / inflammatory disorders, cerebrovascular disorders, oncological disorders, musculoskeletal disorders, neurological disorders, genetic disorders and others. Currently, allogeneic cell therapies for post-transplant infections and cardiovascular disorders dominate the overall market. However, the market for cell therapies used in autoimmune / inflammatory disorders is likely to grow at a relatively higher CAGR.

North America Accounts for the Largest Share of the Market

Based on the key geographical regions, the market is segmented into North America, Europe, and Asia-Pacific and Rest of the World. In the current scenario, North America is likely to capture the largest market share.

Example Players in the Allogeneic Cell Therapy Market

Artiva Biotherapeutics
Allogene Therapeutics
Atara Biotherapeutics
Cellenkos
Cell2Cure
Celularity
Cellular Biomedicine Group
CHABiotech
CRISPR Therapeutics
Fate Therapeutics
Fundamenta Therapeutics
GC Cell
Hope Biosciences
Immunity Bio
Mesoblast
Nanjing Bioheng Biotech
Orca Bio
Pluristem Therapeutics
Poseida Therapeutics
Stemedica Cell Technologies

ALLOGENEIC CELL THERAPY MARKET: RESEARCH COVERAGE

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global allogeneic cell therapy market, focusing on key market segments, including [A] type of cell therapy, [B] source of cell, [C] target indication, [D] therapeutic area and [E] key geographical regions.
Allogeneic Cell Therapies Market Landscape: A comprehensive evaluation of allogeneic cell therapies, based on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] phase of development, [E] route of administration, [F] type of cell therapy, [G] source of cell, [H] dosing frequency, [I] type of therapy, [J] target patient segment, [K] target indication and [L] therapeutic area.
Partnerships and Collaborations: An insightful analysis of the deals inked by stakeholders in allogeneic cell therapy domain, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] type of cell therapy, [D] therapeutic area, [E] type of partner, [F] most active players and [G] geographical distribution of partnership activity.
Funding and Investment Analysis: An in-depth analysis of the fundings raised by companies engaged in this domain, based on relevant parameters, such as [A] year of investment, [B] amount invested, [C] type of funding, [D] type of investor, [E] type of therapy, [F] geographical distribution and [G] most active players.
Clinical Trial Analysis: An insightful analysis of clinical trials related to allogeneic cell therapies, based on several parameters, such as [A] trial registration year, [B] trial status, [C] trial phase, [D] study design, [E] type of sponsor, [F] geography and [G] most active industry and non-industry players.
Key Opinion Leaders (KOLs]: An in-depth analysis that emphasizes the key opinion leaders investigating clinical trials related to allogeneic cell therapies, considering various parameters, such as [A] type of KOL, [B] qualification, [C] type of organization, [D] affiliated organization, [E] geographical location of KOLs and [F] target disease indication.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary Excel Data Packs for all Analytical Modules in the Report
15% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

Product Code: RA100446

1. PREFACE

1.1. Allogeneic Cell Therapy Market Overview

1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Overview of Allogeneic Cell Therapy
3.2. Manufacturing Process of Allogeneic Cell Therapy
3.3. Advantages Offered by Allogeneic Cell Therapy
3.4. Challenges Associated with Allogeneic Cell Therapy
3.5. Recent Developments in Allogeneic Cell Therapy Industry
3.6. Future Perspectives

4. MARKET LANDSCAPE

4.1. Allogeneic Cell Therapies: Market Landscape
- 4.1.1. Analysis by Phase of Development
- 4.1.2. Analysis by Route of Administration
- 4.1.3. Analysis by Type of Cell Therapy
- 4.1.4. Analysis by Source of Cell
- 4.1.5. Analysis by Dosing Frequency
- 4.1.6. Analysis by Type of Therapy
- 4.1.7. Analysis by Target Patient Segment
- 4.1.8. Analysis by Target Indication
- 4.1.9. Analysis by Therapeutic Area
4.2. Allogeneic Cell Therapies: Developer Landscape
- 4.2.1. Analysis by Year of Establishment
- 4.2.2. Analysis by Company Size
- 4.2.3. Analysis by Location of Headquarters
- 4.2.4. Most Active Players: Analysis by Number of Therapies

5. PARTNERSHIPS AND COLLABORATIONS

5.1. Chapter Overview
5.2. Partnership Models
5.3. Allogeneic Cell Therapies: Partnerships and Collaborations
- 5.3.1. Analysis by Year of Partnership
- 5.3.2. Analysis by Type of Partnership
- 5.3.3. Analysis by Year and Type of Partnership
- 5.3.4. Analysis by Type of Cell Therapy
- 5.3.5. Analysis by Therapeutic Area
- 5.3.6. Analysis by Type of Partner
- 5.3.7. Most Active Players: Analysis by Number of Partnerships
- 5.3.8. Analysis by Geography
  - 5.3.8.1. Intercontinental and Intracontinental Deals
  - 5.3.8.2. Local and International Deals

6. FUNDING AND INVESTMENTS

6.1. Chapter Overview
6.2. Types of Funding
6.3. Allogeneic Cell Therapies: Funding and Investments
- 6.3.1. Analysis by Year of Investment
- 6.3.2. Analysis by Amount Invested
- 6.3.3. Analysis by Type of Funding
- 6.3.4. Analysis of Amount Invested by Type of Funding
- 6.3.5. Analysis of Amount Invested by Year and Type of Funding
- 6.3.6. Analysis by Type of Investor
- 6.3.7. Analysis by Type of Therapy
- 6.3.8. Analysis by Geography
- 6.3.9. Leading Investors: Analysis by Number of Instances
- 6.3.10. Most Active Players: Analysis by Number of Instances
- 6.3.11. Most Active Players: Analysis by Amount Invested

7. CLINICAL TRIAL ANALYSIS

7.1. Analysis Methodology and Key Parameters
7.2. Allogeneic Cell Therapies: Clinical Trial Analysis
- 7.2.1. Analysis by Trial Registration Year
- 7.2.2. Analysis by Trial Status
- 7.2.3. Analysis by Trial Registration Year and Trial Status
- 7.2.4. Analysis by Trial Registration Year and Patients Enrolled
- 7.2.5. Analysis by Trial Status and Patients Enrolled
- 7.2.6. Analysis by Trial Phase
- 7.2.7. Analysis by Study Design
- 7.2.8. Analysis by Trial Status, Trial Phase and Geography
- 7.2.9. Analysis by Type of Sponsor
- 7.2.10. Most Active Industry Players: Analysis by Number of Trials
- 7.2.11. Most Active Non-Industry Players: Analysis by Number of Trials
- 7.2.12. Analysis by Geography

8. KEY OPINION LEADERS

8.1. Methodology and Key Parameters
8.2. Allogeneic Cell Therapies: Key Opinion Leaders (KOLs)
- 8.2.1. Analysis by Type of KOL
- 8.2.2. Analysis by Qualification
- 8.2.3. Analysis by Type of Organization
- 8.2.4. Analysis by Affiliated Organization
- 8.2.5. Analysis by Target Disease Indication
- 8.2.6. Analysis by Geographical Location of KOLs
- 8.2.7. Most Prominent KOLs: Peer Group 1 (Principal Investigators)
- 8.2.8. Most Prominent KOLs: Peer Group 2 (Study Directors)
- 8.2.9. Most Prominent KOLs: Peer Group 3 (Study Chair)
- 8.2.10. Most Prominent KOLs: Analysis by RA Score

9. MARKET FORECAST AND OPPORTUNITY ANALYSIS

9.1. Chapter Overview
9.2. Key Assumptions and Methodology
9.3. Global Allogeneic Cell Therapy Market, Till 2035
- 9.3.1. Allogeneic Cell Therapy Market: Distribution by Type of Cell Therapy, Till 2035
  - 9.3.1.1. Allogeneic Cell Therapy Market for Stem Cell Therapies, Till 2035
  - 9.3.1.2. Allogeneic Cell Therapy Market for Virus-specific T-cell Therapies, Till 2035
  - 9.3.1.3. Allogeneic Cell Therapy Market for Regulatory T-cell Therapies, Till 2035
- 9.3.2. Allogeneic Cell Therapy Market: Distribution by Source of Cell, Till 2035
  - 9.3.2.1. Allogeneic Cell Therapy Market for Bone Marrow / Matrix-derived Therapies, Till 2035
  - 9.3.2.2. Allogeneic Cell Therapy Market for Adipose Tissue-derived Therapies, Till 2035
  - 9.3.2.3. Allogeneic Cell Therapy Market for Peripheral Blood-derived Therapies, Till 2035
  - 9.3.2.4. Allogeneic Cell Therapy Market for Umbilical Cord-derived Therapies, Till 2035
  - 9.3.2.5. Allogeneic Cell Therapy Market for Placenta-derived Therapies, Till 2035
  - 9.3.2.6. Allogeneic Cell Therapy Market for Others, Till 2035
- 9.3.3. Allogeneic Cell Therapy Market: Distribution by Target Indication, Till 2035
  - 9.3.3.1. Allogeneic Cell Therapy Market for Infectious Disease, Till 2035
  - 9.3.3.2. Allogeneic Cell Therapy Market for Chronic Heart Failure, Till 2035
  - 9.3.3.3. Allogeneic Cell Therapy Market for Crohn's Disease Till 2035
  - 9.3.3.4. Allogeneic Cell Therapy Market for Ischemic Stroke, Till 2035
  - 9.3.3.5. Allogeneic Cell Therapy Market for Hematological Cancer, Till 2035
  - 9.3.3.6. Allogeneic Cell Therapy Market for Bone Diseases Till 2035
  - 9.3.3.7. Allogeneic Cell Therapy Market for Critical Limb Ischemia, Till 2035
  - 9.3.3.8. Allogeneic Cell Therapy Market for Graft versus Host Disease, Till 2035
  - 9.3.3.9. Allogeneic Cell Therapy Market for Duchenne Muscular Dystrophy, Till 2035
  - 9.3.3.10. Allogeneic Cell Therapy Market for Epidermolysis Bullosa, Till 2035
  - 9.3.3.11. Allogeneic Cell Therapy Market for Diabetic Foot Ulcer, Till 2035
  - 9.3.3.12. Allogeneic Cell Therapy Market for Others, Till 2035
- 9.3.4. Allogeneic Cell Therapy Market: Distribution by Therapeutic Area, Till 2035
  - 9.3.4.1. Allogeneic Cell Therapy Market for Post-Transplant Infections, Till 2035
  - 9.3.4.2. Allogeneic Cell Therapy Market for Cardiovascular Disorders, Till 2035
  - 9.3.4.3. Allogeneic Cell Therapy Market for Autoimmune / Inflammatory Disorders, Till 2035
  - 9.3.4.4. Allogeneic Cell Therapy Market for Cerebrovascular Disorders, Till 2035
  - 9.3.4.5. Allogeneic Cell Therapy Market for Oncological Disorders, Till 2035
  - 9.3.4.6. Allogeneic Cell Therapy Market for Musculoskeletal Disorders, Till 2035
  - 9.3.4.7. Allogeneic Cell Therapy Market for Neurological Disorders, Till 2035
  - 9.3.4.8. Allogeneic Cell Therapy Market for Genetic Disorders, Till 2035
  - 9.3.4.9. Allogeneic Cell Therapy Market for Others, Till 2035
- 9.3.5. Allogeneic Cell Therapy Market: Distribution by Key Geographical Regions, Till 2035
  - 9.3.5.1. Allogeneic Cell Therapy Market in North America, Till 2035
    - 9.3.5.1.1. Allogeneic Cell Therapy Market in the US, Till 2035
    - 9.3.5.1.2. Allogeneic Cell Therapy Market in Canada, Till 2035
  - 9.3.5.2. Allogeneic Cell Therapy Market in Europe, Till 2035
    - 9.3.5.2.1. Allogeneic Cell Therapy Market in the UK, Till 2035
    - 9.3.5.2.2. Allogeneic Cell Therapy Market in Germany, Till 2035
    - 9.3.5.2.3. Allogeneic Cell Therapy Market in France, Till 2035
    - 9.3.5.2.4. Allogeneic Cell Therapy Market in Italy, Till 2035
    - 9.3.5.2.5. Allogeneic Cell Therapy Market in Spain, Till 2035
    - 9.3.5.2.6. Allogeneic Cell Therapy Market in Rest of Europe, Till 2035
  - 9.3.5.3. Allogeneic Cell Therapy Market in Asia-Pacific and Rest of the World, Till 2035
    - 9.3.5.3.1. Allogeneic Cell Therapy Market in India, Till 2035
    - 9.3.5.3.2. Allogeneic Cell Therapy Market in Australia, Till 2035
    - 9.3.5.3.3. Allogeneic Cell Therapy Market in Taiwan, Till 2035
    - 9.3.5.3.4. Allogeneic Cell Therapy Market in Japan, Till 2035
    - 9.3.5.3.5. Allogeneic Cell Therapy Market in Korea, Till 2035
    - 9.3.5.3.6. Allogeneic Cell Therapy Market in Malaysia, Till 2035
    - 9.3.5.3.7. Allogeneic Cell Therapy Market in Israel, Till 2035
9.4. Allogeneic Cell Therapy Market: Product-wise Sales Forecast, Till 2035
- 9.4.1. Revascor / MPC-150-IM / Rexlemestrocel-L
  - 9.4.1.1. Sales Forecast (USD Million)
  - 9.4.1.2. Net Present Value
  - 9.4.1.3. Value Creation Analysis
- 9.4.2. Alofisel / Darvadstrocel / Cx601
  - 9.4.2.1. Sales Forecast (USD Million)
  - 9.4.2.2. Net Present Value
  - 9.4.2.3. Value Creation Analysis
- 9.4.3. MultiStem(R) (Athersys)
  - 9.4.3.1. Sales Forecast (USD Million)
  - 9.4.3.2. Net Present Value
  - 9.4.3.3. Value Creation Analysis
- 9.4.4. Tab-cel(R) / tabelecleucel / ATA129
  - 9.4.4.1. Sales Forecast (USD Million)
  - 9.4.4.2. Net Present Value
  - 9.4.4.3. Value Creation Analysis
- 9.4.5. MDR-101
  - 9.4.5.1. Sales Forecast (USD Million)
  - 9.4.5.2. Net Present Value
  - 9.4.5.3. Value Creation Analysis
- 9.4.6. PLX-PAD
  - 9.4.6.1. Sales Forecast (USD Million)
  - 9.4.6.2. Net Present Value
  - 9.4.6.3. Value Creation Analysis
- 9.4.7. OMISIRGE / Omidubicel-onlv
  - 9.4.7.1. Sales Forecast (USD Million)
  - 9.4.7.2. Net Present Value
  - 9.4.7.3. Value Creation Analysis
- 9.4.8. Orca-T
  - 9.4.8.1. Sales Forecast (USD Million)
  - 9.4.8.2. Net Present Value
  - 9.4.8.3. Value Creation Analysis
- 9.4.9. Ryoncil
  - 9.4.9.1. Sales Forecast (USD Million)
  - 9.4.9.2. Net Present Value
  - 9.4.9.3. Value Creation Analysis
- 9.4.10. Stempeucel(R)
  - 9.4.10.1. Sales Forecast (USD Million)
  - 9.4.10.2. Net Present Value
  - 9.4.10.3. Value Creation Analysis
- 9.4.11. Viralym-M / ALVR105 / Posoleucel
  - 9.4.11.1. Sales Forecast (USD Million)
  - 9.4.11.2. Net Present Value
  - 9.4.11.3. Value Creation Analysis
- 9.4.12. Trinity Evolution(R)
  - 9.4.12.1. Sales Forecast (USD Million)
  - 9.4.12.2. Net Present Value
  - 9.4.12.3. Value Creation Analysis
- 9.4.13. CAP-1002
  - 9.4.13.1. Sales Forecast (USD Million)
  - 9.4.13.2. Net Present Value
  - 9.4.13.3. Value Creation Analysis
- 9.4.14. Osteocel(R) Plus
  - 9.4.14.1. Sales Forecast (USD Million)
  - 9.4.14.2. Net Present Value
  - 9.4.14.3. Value Creation Analysis
- 9.4.15. MPC-06-ID / Rexlemestrocel-L
  - 9.4.15.1. Sales Forecast (USD Million)
  - 9.4.15.2. Net Present Value
  - 9.4.15.3. Value Creation Analysis
- 9.4.16. AB-205 / E-CEL cells
  - 9.4.16.1. Sales Forecast (USD Million)
  - 9.4.16.2. Net Present Value
  - 9.4.16.3. Value Creation Analysis
- 9.4.17. allo-APZ2-OTS
  - 9.4.17.1. Sales Forecast (USD Million)
  - 9.4.17.2. Net Present Value
  - 9.4.17.3. Value Creation Analysis
- 9.4.18. Trinity ELITE
  - 9.4.18.1. Sales Forecast (USD Million)
  - 9.4.18.2. Net Present Value
  - 9.4.18.3. Value Creation Analysis
- 9.4.19. CYP-004
  - 9.4.19.1. Sales Forecast (USD Million)
  - 9.4.19.2. Net Present Value
  - 9.4.19.3. Value Creation Analysis
- 9.4.20. Cytovir CMV T-cells
  - 9.4.20.1. Sales Forecast (USD Million)
  - 9.4.20.2. Net Present Value
  - 9.4.20.3. Value Creation Analysis
- 9.4.21. CARTISTEM(R)
  - 9.4.21.1. Sales Forecast (USD Million)
  - 9.4.21.2. Net Present Value
  - 9.4.21.3. Value Creation Analysis
- 9.4.22. Grafix(R)
  - 9.4.22.1. Sales Forecast (USD Million)
  - 9.4.22.2. Net Present Value
  - 9.4.22.3. Value Creation Analysis
- 9.4.23. ELIXCYTE
  - 9.4.23.1. Sales Forecast (USD Million)
  - 9.4.23.2. Net Present Value
  - 9.4.23.3. Value Creation Analysis
- 9.4.24. TEMCELL(R) HS
  - 9.4.24.1. Sales Forecast (USD Million)
  - 9.4.24.2. Net Present Value
  - 9.4.24.3. Value Creation Analysis
- 9.4.25. ALLO-ASC-DFU
  - 9.4.25.1. Sales Forecast (USD Million)
  - 9.4.25.2. Net Present Value
  - 9.4.25.3. Value Creation Analysis

10. EXECUTIVE INSIGHTS

10.1. Chapter Overview
10.2. Glycostem Therapeutics
- 10.2.1. Company Snapshot
- 10.2.2. Interview Transcript: Troels Jordansen (Chief Executive Officer)
10.3. Mesoblast
- 10.3.1. Company Snapshot
- 10.3.2. Interview Transcript: Eric Rose (Chief Medical Officer)
10.4. Triumvira Immunologics
- 10.4.1. Company Snapshot
- 10.4.2. Interview Transcript: Andreas Bader (Chief Scientific Officer)
10.5. Celyad Oncology
- 10.5.1. Company Snapshot
- 10.5.2. Interview Transcript: Vincent Brichard (Vice President)

11. APPENDIX I: TABULATED DATA

12. APPENDIX I1: LIST OF COMPANIES AND ORGANIZATIONS

Product Code: RA100446

List of Tables

Table 4.1 List of Allogeneic Cell Therapies
Table 4.2 List of Allogeneic Cell Therapies Developers
Table 5.1 Allogeneic Cell Therapies: List of Partnerships and Collaborations, Since 2019
Table 6.1 Allogeneic Cell Therapies: List of Funding and Investments, Since 2019
Table 7.1. Allogeneic Cell Therapies: List of Clinical Trials, Since 2019
Table 8.1. Allogeneic Cell Therapies: List of Key Opinion Leaders (KOLs)
Table 9.1 Allogeneic Cell Therapies: List of Forecasted Therapies
Table 11.1 Market Landscape: Distribution by Phase of Development
Table 11.2 Market Landscape: Distribution by Route of Administration
Table 11.3 Market Landscape: Distribution by Type of Cell Therapy
Table 11.4 Market Landscape: Distribution by Source of Cell
Table 11.5 Market Landscape: Distribution by Dosing Frequency
Table 11.6 Market Landscape: Distribution by Type of Therapy
Table 11.7 Market Landscape: Distribution by Target Patient Segment
Table 11.8 Market Landscape: Distribution by Target Indication
Table 11.9 Market Landscape: Distribution by Therapeutic Area
Table 11.10 Market Landscape: Distribution by Year of Establishment
Table 11.11 Market Landscape: Distribution by Company Size
Table 11.12 Market Landscape: Distribution by Location of Headquarters
Table 11.13 Market Landscape: Distribution by Number of Therapies
Table 11.14 Partnerships and Collaborations: Distribution by Year of Partnership, Since 2019
Table 11.15 Partnerships and Collaborations: Distribution by Type of Partnership
Table 11.16 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 11.17 Partnerships and Collaborations: Distribution by Type of Cell Therapy
Table 11.18 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 11.19 Partnerships and Collaborations: Distribution by Type of Partner
Table 11.20 Most Active Players: Distribution by Number of Partnerships
Table 11.21 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Table 11.22 Partnerships and Collaborations: Local and International Deals
Table 11.23 Funding and Investments: Distribution by Year of Investment, Since 2019
Table 11.24 Funding and Investments: Distribution by Amount Invested (USD Million)
Table 11.25 Funding and Investments: Distribution by Type of Funding
Table 11.26 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
Table 11.27 Funding and Investments: Distribution of Amount Invested by Year and Type of Funding (USD Million)
Table 11.28 Funding and Investments: Distribution by Type of Investor
Table 11.29 Funding and Investments: Distribution by Type of Therapy
Table 11.30 Funding and Investments: Distribution by Geography (Region-wise)
Table 11.31 Funding and Investments: Distribution by Geography (Country-wise)
Table 11.32 Leading Investors: Distribution by Number of Instances
Table 11.33 Most Active Players: Distribution by Number of Instances
Table 11.34 Most Active Players: Distribution by Amount Invested (USD Million)
Table 11.35 Clinical Trial Analysis: Distribution by Trial Registration Year, Since 2019
Table 11.36 Clinical Trial Analysis: Distribution by Trial Status
Table 11.37 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 11.38 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled
Table 11.39 Clinical Trial Analysis: Distribution by Trial Status and Patients Enrolled
Table 11.40 Clinical Trial Analysis: Distribution by Trial Phase
Table 11.41 Clinical Trial Analysis: Distribution by Study Design
Table 11.42 Clinical Trial Analysis: Distribution by Trial Status, Trial Phase and Geography
Table 11.43 Clinical Trial Analysis: Distribution by Type of Sponsor
Table 11.44 Most Active Industry Players: Analysis by Number of Trials
Table 11.45 Most Active Non-Industry Players: Analysis by Number of Trials
Table 11.46 Clinical Trial Analysis: Distribution by Geography and Trial Status (Number of Trials)
Table 11.47 Clinical Trial Analysis: Distribution by Geography and Trial Status (Patients Enrolled)
Table 11.48 Allogeneic Cell Therapies KOL Analysis: Distribution by Type of KOL
Table 11.49 Allogeneic Cell Therapies KOL Analysis: Distribution by Qualification
Table 11.50 Allogeneic Cell Therapies KOL Analysis: Distribution by Type of Organization
Table 11.51 Allogeneic Cell Therapies KOL Analysis: Distribution by Affiliated Organization
Table 11.52 Allogeneic Cell Therapies KOL Analysis: Distribution by Target Disease Indication
Table 11.53 Allogeneic Cell Therapies KOL Analysis: Distribution by Geographical Location of KOLs
Table 11.54 Most Prominent KOLs: Distribution by RA score
Table 11.55 Global Allogeneic Cell Therapy Market: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.56 Allogeneic Cell Therapy Market: Distribution by Type of Cell Therapy, Till 2035 (USD Million)
Table 11.57 Allogeneic Cell Therapy Market for Stem Cell Therapies: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.58 Allogeneic Cell Therapies Market for Virus-specific T-cell Therapies: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.59 Allogeneic Cell Therapy Market for Regulatory T-cell Therapies: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.60 Allogeneic Cell Therapy Market: Distribution by Source of Cell, Till 2035 (USD Million)
Table 11.61 Allogeneic Cell Therapy Market for Bone Marrow / Matrix-derived Therapies: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.62 Allogeneic Cell Therapy Market for Adipose Tissue-derived Therapies: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.63 Allogeneic Cell Therapy Market for Umbilical Cord-derived Therapies: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.64 Allogeneic Cell Therapy Market for Peripheral Blood-derived Therapies: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.65 Allogeneic Cell Therapy Market for Placenta-derived Therapies: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.66 Allogeneic Cell Therapy Market for Others: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.67 Allogeneic Cell Therapy Market: Distribution by Target Indication, Till 2035 (USD Million)
Table 11.68 Allogeneic Cell Therapy Market for Infectious Disease: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.69 Allogeneic Cell Therapy Market for Chronic Heart Failure: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.70 Allogeneic Cell Therapy Market for Crohn's Disease: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.71 Allogeneic Cell Therapy Market for Ischemic Stroke: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.72 Allogeneic Cell Therapy Market for Hematological Cancer: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.73 Allogeneic Cell Therapy Market for Bone Disease: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.74 Allogeneic Cell Therapy Market for Critical Limb Ischemia: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.75 Allogeneic Cell Therapy Market for Graft versus Host Disease: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.76 Allogeneic Cell Therapy Market for Duchenne Muscular Dystrophy: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.77 Allogeneic Cell Therapy Market for Epidermolysis Bullosa: Conservative, Base 8and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.78 Allogeneic Cell Therapy Market for Diabetic Foot Ulcer: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.79 Allogeneic Cell Therapy Market for Others: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.80 Allogeneic Cell Therapy Market: Distribution by Therapeutic Area, Till 2035 (USD Million)
Table 11.81 Allogeneic Cell Therapy Market for Post Transplant Infections: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.82 Allogeneic Cell Therapy Market for Cardiovascular Disorders: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.83 Allogeneic Cell Therapy Market for Autoimmune / Inflammatory Disorders: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.84 Allogeneic Cell Therapy Market for Cerebrovascular Disorders: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.85 Allogeneic Cell Therapy Market for Oncological Disorders: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.86 Allogeneic Cell Therapy Market for Musculoskeletal Disorders: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.87 Allogeneic Cell Therapy Market for Neurological Disorders: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.88 Allogeneic Cell Therapy Market for Genetic Disorders: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.89 Allogeneic Cell Therapy Market for Others: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.90 Allogeneic Cell Therapy Market: Distribution by Key Geographical Regions, Till 2035 (USD Million)
Table 11.91 Allogeneic Cell Therapy Market in North America: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.92 Allogeneic Cell Therapy Market in the US: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.93 Allogeneic Cell Therapy Market in Canada: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.94 Allogeneic Cell Therapy Market in Europe: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.95 Allogeneic Cell Therapy Market in the UK: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.96 Allogeneic Cell Therapy Market in Germany: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.97 Allogeneic Cell Therapy Market in France: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.98 Allogeneic Cell Therapy Market in Italy: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.99 Allogeneic Cell Therapy Market in Spain: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.100 Allogeneic Cell Therapy Market in Rest of Europe: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.101 Allogeneic Cell Therapy Market in Asia-Pacific and Rest of the World: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.102 Allogeneic Cell Therapy Market in India: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.103 Allogeneic Cell Therapy Market in Australia: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.104 Allogeneic Cell Therapy Market in Taiwan: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.105 Allogeneic Cell Therapy Market in Japan: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.106 Allogeneic Cell Therapy Market in Korea: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.107 Allogeneic Cell Therapy Market in Malaysia: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.108 Allogeneic Cell Therapy Market in Israel: Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.109 Revascor / MPC-150-IM / Rexlemestrocel-L (Mesoblast): Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.110 Alofisel / Darvadstrocel / Cx601 (Takeda): Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.111 MultiStem(R) (Athersys): Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.112 Tab-cel(R) / tabelecleucel / ATA129 (Atara Biotherapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.113 MDR-101 (Medeor Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.114 PLX-PAD (Pluristem Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.115 OMISIRGE / Omidubicel-onlv (Gamida Cell): Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.116 Orca-T (Orca Bio): Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.117 Ryoncil (Mesoblast): Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.118 Stempeucel(R) (Stempeutics Research): Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.119 Viralym-M / ALVR105 / Posoleucel (Allovir): Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.120 Trinity Evolution(R) (Orthofix): Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.121 CAP-1002 (Capricor Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.122 Osteocel(R) Plus (NuVasive): Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.123 MPC-06-ID / Rexlemestrocel-L (Mesoblast): Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.124 AB-205 / E-CEL cells (Angiocrine Bioscience): Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.125 allo-APZ2-OTS (RHEACELL): Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.126 Trinity ELITE (Orthofix): Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.127 CYP-004 (Cynata Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.128 Cytovir CMV T-cells (Kuur Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.129 CARTISTEM(R) (Medipost): Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.130 Grafix(R) (Osiris Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.131 ELIXCYTE (UnicoCell Biomed): Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.132 TEMCELL(R) HS (JCR Pharmaceutical, Mesoblast): Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 11.133 ALLO-ASC-DFU (Anterogen): Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)

List of Figures

Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Partnerships and Collaborations
Figure 2.3 Executive Summary: Funding and Investment Analysis
Figure 2.4 Executive Summary: Clinical Trial Analysis
Figure 2.5 Executive Summary: Key Opinion Leaders
Figure 2.6 Executive Summary: Market Sizing and Opportunity Analysis
Figure 3.1 Manufacturing Process of Allogeneic Cell Therapy
Figure 3.2 Advantages Offered by Allogeneic Cell Therapy
Figure 3.3 Challenges Associated with Allogeneic Cell Therapy
Figure 4.1 Allogeneic Cell Therapies: Distribution by Phase of Development
Figure 4.2 Allogeneic Cell Therapies: Distribution by Route of Administration
Figure 4.3 Allogeneic Cell Therapies: Distribution by Type of Cell Therapy
Figure 4.4 Allogeneic Cell Therapies: Distribution by Source of Cell
Figure 4.5 Allogeneic Cell Therapies: Distribution by Dosing Frequency
Figure 4.6 Allogeneic Cell Therapies: Distribution by Type of Therapy
Figure 4.7 Allogeneic Cell Therapies: Distribution by Target Patient Segment
Figure 4.8 Allogeneic Cell Therapies: Distribution by Target Indication
Figure 4.9 Allogeneic Cell Therapies: Distribution by Therapeutic Area
Figure 4.10 Allogeneic Cell Therapies Developers: Distribution by Year of Establishment
Figure 4.11 Allogeneic Cell Therapies Developers: Distribution by Company Size
Figure 4.12 Allogeneic Cell Therapies Developers: Distribution by Location of Headquarters
Figure 4.13 Most Active Players: Distribution by Number of Therapies
Figure 5.1 Partnerships and Collaborations: Distribution by Year of Partnership, Since 2019
Figure 5.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 5.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 5.4 Partnerships and Collaborations: Distribution by Type of Cell Therapy
Figure 5.5 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 5.6 Partnerships and Collaborations: Distribution by Type of Partner
Figure 5.7 Most Active Players: Distribution by Number of Partnerships
Figure 5.8 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 5.9 Partnerships and Collaborations: Local and International Deals
Figure 6.1 Funding and Investments: Distribution by Year of Investment, Since 2019
Figure 6.2 Funding and Investments: Distribution by Amount Invested (USD Million)
Figure 6.3 Funding and Investments: Distribution by Type of Funding
Figure 6.4 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 6.5 Funding and Investments: Distribution of Amount Invested by Year and Type of Funding (USD Million)
Figure 6.6 Funding and Investments: Distribution by Type of Investor
Figure 6.7 Funding and Investments: Distribution by Type of Therapy
Figure 6.8 Funding and Investments: Distribution by Geography (Region-wise)
Figure 6.9 Funding and Investments: Distribution by Geography (Country-wise)
Figure 6.10 Leading Investors: Distribution by Number of Instances
Figure 6.11 Most Active Players: Distribution by Number of Instances
Figure 6.12 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 7.1 Clinical Trial Analysis: Scope and Methodology
Figure 7.2 Clinical Trial Analysis: Distribution by Trial Registration Year, Since 2019
Figure 7.3 Clinical Trial Analysis: Distribution by Trial Status
Figure 7.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 7.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled
Figure 7.6 Clinical Trial Analysis: Distribution by Trial Status and Patients Enrolled
Figure 7.7 Clinical Trial Analysis: Distribution by Trial Phase
Figure 7.8 Clinical Trial Analysis: Distribution by Study Design
Figure 7.9 Clinical Trial Analysis: Distribution by Trial Status, Trial Phase and Geography
Figure 7.10 Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 7.11 Most Active Industry Players: Analysis by Number of Trials
Figure 7.12 Most Active Non-Industry Players: Analysis by Number of Trials
Figure 7.13 Clinical Trial Analysis: Distribution by Geography and Trial Status (Number of Trials)
Figure 7.14 Clinical Trial Analysis: Distribution by Geography and Trial Status (Patients Enrolled)
Figure 8.1 Allogeneic Cell Therapies KOL Analysis: Distribution by Type of KOL
Figure 8.2 Allogeneic Cell Therapies KOL Analysis: Distribution by Qualification
Figure 8.3 Allogeneic Cell Therapies KOL Analysis: Distribution by Type of Organization
Figure 8.4 Allogeneic Cell Therapies KOL Analysis: Distribution by Affiliated Organization
Figure 8.5 Allogeneic Cell Therapies KOL Analysis: Distribution by Target Disease Indication
Figure 8.6 Allogeneic Cell Therapies KOL Analysis: Geographical Distribution of KOLs (Region-wise)
Figure 8.7 Allogeneic Cell Therapies KOL Analysis: Geographical Distribution of KOLs (Country-wise)
Figure 8.8 Most Prominent KOLs: Peer Group 1 (Principal Investigators)
Figure 8.9 Most Prominent KOLs: Peer Group 2 (Study Directors)
Figure 8.10 Most Prominent KOLs: Peer Group 3 (Study Chair)
Figure 8.11 Most Prominent KOLs: Distribution by RA score
Figure 9.1 Global Allogeneic Cell Therapy Market, Till 2035 (USD Million)
Figure 9.2 Allogeneic Cell Therapy Market: Distribution by Type of Cell Therapy, Till 2035 (USD Million)
Figure 9.3 Allogeneic Cell Therapy Market for Stem Cell Therapies, Till 2035 (USD Million)
Figure 9.4 Allogeneic Cell Therapy Market for Virus-Specific T-cell Therapies, Till 2035 (USD Million)
Figure 9.5 Allogeneic Cell Therapy Market for Regulatory T-cell Therapies, Till 2035 (USD Million)
Figure 9.6 Allogeneic Cell Therapy Market: Distribution by Source of Cell, Till 2035 (USD Million)
Figure 9.7 Allogeneic Cell Therapy Market for Bone Marrow / Matrix-derived Therapies, Till 2035 (USD Million)
Figure 9.8 Allogeneic Cell Therapy Market for Adipose Tissue-derived Therapies, Till 2035 (USD Million)
Figure 9.9 Allogeneic Cell Therapy Market for Peripheral Blood-derived Therapies, Till 2035 (USD Million)
Figure 9.10 Allogeneic Cell Therapy Market for Umbilical Cord-derived Therapies, Till 2035 (USD Million)
Figure 9.11 Allogeneic Cell Therapy Market for Placenta-derived Therapies, Till 2035 (USD Million)
Figure 9.12 Allogeneic Cell Therapy Market for Others, Till 2035 (USD Million)
Figure 9.13 Allogeneic Cell Therapy Market: Distribution by Target Indication, Till 2035 (USD Million)
Figure 9.14 Allogeneic Cell Therapy Market for Infectious Disease, Till 2035 (USD Million)
Figure 9.15 Allogeneic Cell Therapy Market for Chronic Heart Failure, Till 2035 (USD Million)
Figure 9.16 Allogeneic Cell Therapy Market for Crohn's Disease Till 2035 (USD Million)
Figure 9.17 Allogeneic Cell Therapy Market for Ischemic Stroke, Till 2035 (USD Million)
Figure 9.18 Allogeneic Cell Therapy Market for Hematological Cancer, Till 2035 (USD Million)
Figure 9.19 Allogeneic Cell Therapy Market for Bone Disease, Till 2035 (USD Million)
Figure 9.20 Allogeneic Cell Therapy Market for Critical Limb Ischemia, Till 2035 (USD Million)
Figure 9.21 Allogeneic Cell Therapy Market for Graft versus Host Disease, Till 2035 (USD Million)
Figure 9.22 Allogeneic Cell Therapy Market for Duchenne Muscular Dystrophy, Till 2035 (USD Million)
Figure 9.23 Allogeneic Cell Therapy Market for Epidermolysis Bullosa, Till 2035 (USD Million)
Figure 9.24 Allogeneic Cell Therapy Market for Diabetic Foot Ulcer, Till 2035 (USD Million)
Figure 9.25 Allogeneic Cell Therapy Market for Others, Till 2035 (USD Million)
Figure 9.26 Allogeneic Cell Therapy Market: Distribution by Therapeutic Area, Till 2035 (USD Million)
Figure 9.27 Allogeneic Cell Therapy Market for Post-Transplant Infections, Till 2035 (USD Million)
Figure 9.28 Allogeneic Cell Therapy Market for Cardiovascular Disorders, Till 2035 (USD Million)
Figure 9.29 Allogeneic Cell Therapy Market for Autoimmune / Inflammatory Disorders Till 2035 (USD Million)
Figure 9.30 Allogeneic Cell Therapy Market for Cerebrovascular Disorders, Till 2035 (USD Million)
Figure 9.31 Allogeneic Cell Therapy Market for Oncological Disorders, Till 2035 (USD Million)
Figure 9.32 Allogeneic Cell Therapy Market for Musculoskeletal Disorders, Till 2035 (USD Million)
Figure 9.33 Allogeneic Cell Therapy Market for Neurological Disorders, Till 2035 (USD Million)
Figure 9.34 Allogeneic Cell Therapy Market for Genetic Disorders, Till 2035 (USD Million)
Figure 9.35 Allogeneic Cell Therapy Market for Others, Till 2035 (USD Million)
Figure 9.36 Allogeneic Cell Therapy Market: Distribution by Key Geographical Regions, Till 2035 (USD Million)
Figure 9.37 Allogeneic Cell Therapy Market in North America, Till 2035 (USD Million)
Figure 9.38 Allogeneic Cell Therapy Market in the US, Till 2035 (USD Million)
Figure 9.39 Allogeneic Cell Therapy Market in Canada, Till 2035 (USD Million)
Figure 9.40 Allogeneic Cell Therapy Market in Europe, Till 2035 (USD Million)
Figure 9.41 Allogeneic Cell Therapy Market in the UK, Till 2035 (USD Million)
Figure 9.42 Allogeneic Cell Therapy Market in Germany, Till 2035 (USD Million)
Figure 9.43 Allogeneic Cell Therapy Market in France, Till 2035 (USD Million)
Figure 9.44 Allogeneic Cell Therapy Market in Spain, Till 2035 (USD Million)
Figure 9.45 Allogeneic Cell Therapy Market in Italy, Till 2035 (USD Million)
Figure 9.46 Allogeneic Cell Therapy Market in Rest of Europe, Till 2035 (USD Million)
Figure 9.47 Allogeneic Cell Therapy Market in Asia-Pacific and Rest of the World, Till 2035 (USD Million)
Figure 9.48 Allogeneic Cell Therapy Market in India, Till 2035 (USD Million)
Figure 9.49 Allogeneic Cell Therapy Market in Australia, Till 2035 (USD Million)
Figure 9.50 Allogeneic Cell Therapy Market in Taiwan, Till 2035 (USD Million)
Figure 9.51 Allogeneic Cell Therapy Market in Japan, Till 2035 (USD Million)
Figure 9.52 Allogeneic Cell Therapy Market in Korea, Till 2035 (USD Million)
Figure 9.53 Allogeneic Cell Therapy Market in Malaysia, Till 2035 (USD Million)
Figure 9.54 Allogeneic Cell Therapy Market in Israel, Till 2035 (USD Million)
Figure 9.55 Revascor / MPC-150-IM / Rexlemestrocel-L (Mesoblast): Sales Forecast, Till 2035 (USD Million)
Figure 9.56 Alofisel / Darvadstrocel / Cx601 (Takeda): Sales Forecast, Till 2035 (USD Million)
Figure 9.57 MultiStem(R) (Athersys): Sales Forecast, Till 2035 (USD Million)
Figure 9.58 Tab-cel(R) / tabelecleucel / ATA129 (Atara Biotherapeutics): Sales Forecast, Till 2035 (USD Million)
Figure 9.59 MDR-101 (Medeor Therapeutics): Sales Forecast, Till 2035 (USD Million)
Figure 9.60 PLX-PAD (Pluristem Therapeutics): Sales Forecast, Till 2035 (USD Million)
Figure 9.61 OMISIRGE / Omidubicel-onlv (Gamida Cell): Sales Forecast, Till 2035 (USD Million)
Figure 9.62 Orca-T (Orca Bio): Sales Forecast, Till 2035 (USD Million)
Figure 9.63 Ryoncil (Mesoblast): Sales Forecast, Till 2035 (USD Million)
Figure 9.64 Stempeucel(R) (Stempeutics Research): Sales Forecast, Till 2035 (USD Million)
Figure 9.65 Viralym-M / ALVR105 / Posoleucel (Allovir): Sales Forecast, Till 2035 (USD Million)
Figure 9.66 Trinity Evolution(R) (Orthofix): Sales Forecast, Till 2035 (USD Million)
Figure 9.67 CAP-1002 (Capricor Therapeutics): Sales Forecast, Till 2035 (USD Million)
Figure 9.68 Osteocel(R) Plus (NuVasive): Sales Forecast, Till 2035 (USD Million)
Figure 9.69 MPC-06-ID / Rexlemestrocel-L (Mesoblast): Sales Forecast, Till 2035 (USD Million)
Figure 9.70 AB-205 / E-CEL cells (Angiocrine Bioscience): Sales Forecast, Till 2035 (USD Million)
Figure 9.71 allo-APZ2-OTS (RHEACELL): Sales Forecast, Till 2035 (USD Million)
Figure 9.72 Trinity ELITE (Orthofix): Sales Forecast, Till 2035 (USD Million)
Figure 9.73 CYP-004 (Cynata Therapeutics): Sales Forecast, Till 2035 (USD Million)
Figure 9.74 Cytovir CMV T-cells (Kuur Therapeutics): Sales Forecast, Till 2035 (USD Million)
Figure 9.75 CARTISTEM(R) (Medipost): Sales Forecast, Till 2035 (USD Million)
Figure 9.76 Grafix(R) (Osiris Therapeutics): Sales Forecast, Till 2035 (USD Million)
Figure 9.77 ELIXCYTE (UnicoCell Biomed): Sales Forecast, Till 2035 (USD Million)
Figure 9.78 TEMCELL(R) HS (JCR Pharmaceutical / Mesoblast): Sales Forecast, Till 2035 (USD Million)
Figure 9.79 ALLO-ASC-DFU (Anterogen): Sales Forecast, Till 2035 (USD Million)

Allogeneic Cell Therapy Market by Type of Cell Therapy, Source of Cell, Target Indication, Therapeutic Area, and Key Geographical Regions

Description

Table of Contents

List of Tables

ALLOGENEIC CELL THERAPY MARKET: OVERVIEW

ALLOGENEIC CELL THERAPY MARKET: GROWTH AND TRENDS

ALLOGENEIC CELL THERAPY MARKET: KEY INSIGHTS

ALLOGENEIC CELL THERAPY MARKET: KEY SEGMENTS

Example Players in the Allogeneic Cell Therapy Market

ALLOGENEIC CELL THERAPY MARKET: RESEARCH COVERAGE

KEY QUESTIONS ANSWERED IN THIS REPORT

REASONS TO BUY THIS REPORT

ADDITIONAL BENEFITS

TABLE OF CONTENTS

1. PREFACE

1.1. Allogeneic Cell Therapy Market Overview

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. MARKET LANDSCAPE

5. PARTNERSHIPS AND COLLABORATIONS

6. FUNDING AND INVESTMENTS

7. CLINICAL TRIAL ANALYSIS

8. KEY OPINION LEADERS

9. MARKET FORECAST AND OPPORTUNITY ANALYSIS

10. EXECUTIVE INSIGHTS

11. APPENDIX I: TABULATED DATA

12. APPENDIX I1: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

List of Figures